Table 1.
Serum proteins bind to AAV9
| Accession | Description | Fold increase |
|---|---|---|
| P02671 | Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 | 4.945652 |
| P02675 | Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 SV=2 Fibrinogen gamma chain OS=Homo sapiens GN=FGG PE=1 |
4.974026 |
| P02679 | SV=3 Fibrinogen gamma chain (Fragment) OS=Homo sapiens |
4.853614 |
| C9JU00 | GN=FGG PE=2 SV=1 | 8.362319 |
| P02751 | Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=4 | 5.405263 |
| P00747 | Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2 Platelet factor 4 variant OS=Homo sapiens GN=PF4V1 PE=1 |
3.232278 |
| P10720 | SV=1 | 1.466667 |
| P04275 | von Willebrand factor OS=Homo sapiens GN=VWF PE=1 SV=4 Alpha-1-acid glycoprotein 2 OS=Homo sapiens GN=ORM2 |
ND |
| P19652 | PE=1 SV=2 | ND |
ND: indicates no detection of protein in control group
➢ Several serum proteins have a potential effect on AAV vascular permeability.
➢ Serum proteins enhance AAV9 global transduction in mice after systemic administration.
➢ Cryoprecipitate augment AAV9 global transduction in mice.
➢ Fibrinogen and cryoprecipitate slow down the clearance of AAV9 vector in the blood.